Combination of (Anti-her2 antibody)-drug conjugate and her dimerization inhibitor

NZ835250APending Publication Date: 2026-07-31DAIICHI SANKYO CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: NZ835250
Authority / Receiving Office: NZ · NZ
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2020-07-20
Filing Date: 2021-07-19
Publication Date: 2026-07-31

Application Information

Patent Timeline

20 Jul 2020

Priority

19 Jul 2021

Application

NZ835250

31 Jul 2026

Publication

NZ835250A

IPC: A61K47/68; A61K31/4745; A61K39/395; A61P35/00; A61P35/02; A61P43/00; C07K16/30; C12N15/13

Inventors: KAMAI YASUKI

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Smart Images

Figure 1_ABST

Patent Text Reader

Abstract

A pharmaceutical composition characterized in that a combination of an (anti-HER2 antibody)-drug conjugate and a HER dimerization inhibitor is administered, in which the (anti-HER2 antibody)-drug conjugate comprises a drug linker represented by the formula shown below (wherein A represents a binding position to an anti-HER2 antibody) and an anti-HER2 antibody bonded to each other through a thioether bond; and / or a treatment method characterized in that a combination of the (anti-HER2 antibody)-drug conjugate and the HER dimerization inhibitor is administered to an individual.

Need to check novelty before this filing date? Find Prior Art